Experiencia con sunitinib en cáncer de próstata metastásico hormonorresistente sin respuesta a docetaxel

despite the limits of this experience, we can say that Sunitinib appears to be an active and safe option in patients with hormone-refractory prostate cancer that is resistant to chemotherapy with Docetaxel.